Introduction
Astrocytic gliomas are the most common primary brain cancer [1] , with a yearly incidence of 3-5 per 100 000 people [2] . These gliomas occur in all age groups but are most prevalent in adults over 45 years of age [3] . Typical presentation includes headaches, seizures, focal neurological deficits, memory loss, and sometimes personality changes or confusion [2, 4, 5] . Cellular features of malignant gliomas include unrestricted proliferation, extensive invasion, neovascularization, necrosis, and resistance to apoptosis [1, 6] . Gliomas have the unique ability to diffusely invade and infiltrate surrounding brain tissue, intertwining themselves among native cells and so making complete surgical resection typically impossible [7] . The only life-prolonging measures that are somewhat effective are surgical resection followed by radiation and chemotherapy with temozolomide (TMZ) [8, 9] . Tumors typically recur after an average of only 6.9 months [8] , resulting in a median patient survival of just 12-15 months following diagnosis [10] .
Gliomas are often heterogeneous, both phenotypically and with regards to gene expression [11] . Numerous genetic mutations have been identified [11] , yet it has been impossible to define a single disease-initiating event. The diversity of mutations has been an obstacle in developing animal models for laboratory investigations that fully replicate the human disease and has hampered the adoption of a universal clinical treatment plan. Recent research on the cell of origin for these tumors suggests that gliomas originate from stem or neural precursor cells as opposed to differentiated glial cells or glial progenitor cells, as previously believed [12, 13] . Indeed, stem and stem-like cells isolated from human brain tumors can give rise to glioma cells, as well as to neurons, astrocytes, and oligodendrocytes [14] [15] [16] . Stem-like cells isolated from patient biopsies can generate gliomas in animals that harbor cytogenic and molecular characteristics of the original tumor [16] . However, astrocytes are capable of undergoing symmetric division and can amplify significantly in the postnatal brain [17] , raising the possibility that gene mutations in this astrocytic pool give rise to astrocytic gliomas. We refer readers interested in the origin of gliomas to excellent recent reviews on this topic [18] [19] [20] [21] [22] .
Molecular analysis has identified several specific genetic alterations in gliomas. This in turn has led to the development of new drugs or the use of already US Food and Drug Administration (FDA)-approved compounds that target the affected proteins in these tumors. In this review, we highlight important findings regarding the unique biology of this cancer from a neuroscience perspective, illustrating how these insights have shaped new clinical trials that are providing hope for much needed and more efficacious treatment options. The featured examples suggest that gliomas share many biological traits with nonmalignant brain cells and that their biology can only be understood in the context of their host tissue. We suggest that gliomas represent a rapidly progressive neurodegenerative disorder that causes a loss of brain function by exploiting signaling mechanisms that are unique to the brain and not typically found in other cancers.
The glioma-vascular relationship and interdependence Most solid cancers, including gliomas, induce new blood vessel growth to satisfy their energy demands, a process known as neovascularization. This typically involves sprouting of existing blood vessels and is stimulated by tumor-released angiogenic factors, such as vascular endothelial growth factor (VEGF) [23] [24] [25] . Disruption of angiogenic signals is widely pursued as a therapeutic strategy to slow tumor growth [26] [27] [28] . Malignant gliomas are also highly vascularized, often forming glomeruloid bodies, which are capillary buds lined with endothelial cells undergoing VEGF-mediated hyperplasia [23, 29] , initially suggesting that the same anti-angiogenic strategies pursued elsewhere would be promising in treating gliomas.
Glioma-derived endothelial cells
Recent studies, however, suggest that the neovascularization occurs quite differently in gliomas compared with
